moDC-Targeted Mucosal Vaccine Adjuvant for Durable Lung Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are few effective mucosal vaccines due to challenges in developing safe and potent mucosal adjuvants.
Innovation Solution
A vaccine composition comprising an antigen, a cyclic dinucleotide (CDN), soluble tumor necrosis factor (TNF), and a CD64 antibody or antibody fragment, targeting monocyte-derived dendritic cells (moDCs) to induce lung mucosal antibody responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mucosal vaccines are developed to induce protective immunity against mucosal pathogens, then vaccine efficacy is improved, but development of safe and effective mucosal adjuvants becomes more difficult
Solution Approach 1:
The patent uses monocyte-derived dendritic cells (moDCs) as intermediary cells to bridge the gap between the vaccine antigen and the immune system. moDCs are targeted specifically to process and present antigen in the mucosal tissue, facilitating effective immune response without requiring complex adjuvant formulations. This intermediary approach simplifies vaccine development while maintaining high efficacy.
Solution Approach 2:
The patent applies local quality by targeting moDCs specifically in the mucosal tissue environment rather than using system-wide adjuvants. The vaccine composition is designed to act locally at the mucosal surface, inducing protective immunity precisely where needed against mucosal pathogens, thereby improving efficacy without the complexity of systemic adjuvant development.
2Productivity
If moDCs are targeted to present antigen, then antibody response is enhanced, but specificity of immune response may be reduced
Solution Approach 1:
The patent employs parameter changes by modulating the functional state of moDCs through targeted cytokine signaling (e.g., CD40L, CD70, CD27 interactions). These parameter modifications enhance the antibody response capability of moDCs while maintaining their specificity for pathogen antigens. The controlled adjustment of moDC activation parameters ensures both high antibody production and specific immune response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Generates efficacious vaccine responses and long-term memory responses on mucosal surfaces, enhancing protection against pathogens.
Implementation Method 1
a CD64 antibody or antibody fragment, targeting monocyte-derived dendritic cells (moDCs)
Implementation Method 2
a cyclic dinucleotide (CDN), soluble tumor necrosis factor (TNF), and a CD64 antibody or antibody fragment, targeting monocyte-derived dendritic cells (moDCs)
Implementation Method 3
Generates efficacious vaccine responses and long-term memory responses on mucosal surfaces, enhancing protection against pathogens
Data Source
AI summary
Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.